NAVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), Navidea Biopharmaceuticals's share price is $0.03187. Navidea Biopharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2023 was $-0.03. Hence, Navidea Biopharmaceuticals's PB Ratio of today is .
The historical rank and industry rank for Navidea Biopharmaceuticals's PB Ratio or its related term are showing as below:
During the past 13 years, Navidea Biopharmaceuticals's highest PB Ratio was 463.33. The lowest was 3.23. And the median was 11.13.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Navidea Biopharmaceuticals was 78.70% per year. The lowest was -203.70% per year. And the median was -15.95% per year.
The historical data trend for Navidea Biopharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 11.78 | - | 44.79 | - | - |
Navidea Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Navidea Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Navidea Biopharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Navidea Biopharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2023) |
= | 0.03187 | / | -0.033 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Navidea Biopharmaceuticals (OTCPK:NAVB) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Craig Dais | officer: Chief Financial Officer | 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017 |
Dana J Moss | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Jill Stefanelli | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Josh M Wilson | director | 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017 |
Scott John K Jr. | director, 10 percent owner | 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121 |
Agnieszka Winkler | director | C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281 |
Thomas F Farb | director | C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116 |
Michel Mikhail | officer: Chief Regulatory Officer | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Malcolm G Witter | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Alexander L Cappello | director | C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301 |
Amit Bhalla | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Joel H. Kaufman | officer: Chief Business Officer | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Jed Latkin | officer: Interim COO | 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
Claudine Bruck | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552 |
From GuruFocus
By PRNewswire PRNewswire • 05-22-2020
By ACCESSWIRE AccessWire • 04-12-2019
By Monica Wolfe Monica Wolfe • 03-18-2013
By PRNewswire PRNewswire • 05-22-2020
By PRNewswire PRNewswire • 10-29-2019
By GF Value GF Value • 04-06-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.